{
  "node_id": "china-nmpa-drug-registration-regulation-2020",
  "title": "China NMPA Drug Registration Regulation 2020 - Marketing Authorisation Holder System and Priority Review",
  "domain": "Pharmaceuticals & Life Sciences",
  "version": "1.0.0",
  "last_updated": "2026-05-09",
  "bluf": "China's Drug Registration Regulation (Order No. 27, 1 July 2020) issued by the National Medical Products Administration (NMPA - formerly CFDA) establishes the Marketing Authorisation Holder (MAH) system separating drug approval from…",
  "paywall": {
    "status": "LOCKED",
    "unlock_cost_usd": "0.01",
    "skyfire_id": "41779894-ece2-4163-9761-b3b1b76e19b0"
  },
  "crosswalks": {
    "_available_keys": [
      "related_frameworks",
      "industry_mapping",
      "eu_ai_act_relevance"
    ],
    "_note": "Full crosswalk values included in vault response"
  },
  "dependencies": [
    "fda-21-cfr-210-211-current-good-manufacturing-practice"
  ],
  "primary_citations_count": 6,
  "workflow_steps_count": 9,
  "schema_fields_count": 18,
  "citation_preview": [
    {
      "title": "Drug Registration Regulation (NMPA Order No. 27, 2020) - NMPA",
      "url": "https://english.nmpa.gov.cn/",
      "section": "Article 4 (drug classification); Articles 68-78 (priority review); Article 84 (data exclusivity 6 years); Chapter VI (imported drugs); Chapter VIII (post-approval changes); Chapter IX (pharmacovigilance)"
    },
    {
      "title": "Drug Administration Law 2019 (Revised) - National People's Congress",
      "url": "https://english.nmpa.gov.cn/",
      "section": "Article 77 (MAH pharmacovigilance obligations); Article 98 (GMP compliance mandatory); Chapter XI (administrative and criminal penalties up to CNY 3 million)"
    }
  ]
}